Výsledky vyhledávání - Robert Z. Orlowski

Upřesnit hledání
  1. 1
    The role of the ubiquitin-proteasome pathway in apoptosis

    The role of the ubiquitin-proteasome pathway in apoptosis Autor Robert Z. Orlowski

    Vydáno 1999
    Získat plný text Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  2. 2
    NF-κB as a therapeutic target in cancer

    NF-κB as a therapeutic target in cancer Autor Robert Z. Orlowski, Albert S. Baldwin

    Vydáno 2002
    Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  3. 3
    The role of the ubiquitination-proteasome pathway in breast cancer: Applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer

    The role of the ubiquitination-proteasome pathway in breast cancer: Applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer Autor Robert Z. Orlowski, Elizabeth Claire Dees

    Vydáno 2002
    Získat plný text Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  4. 4
    The Immunoproteasome as a Target in Hematologic Malignancies

    The Immunoproteasome as a Target in Hematologic Malignancies Autor Deborah J. Kuhn, Robert Z. Orlowski

    Vydáno 2012
    Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  5. 5
    Proteasome inhibitors in the treatment of multiple myeloma

    Proteasome inhibitors in the treatment of multiple myeloma Autor Jatin J. Shah, Robert Z. Orlowski

    Vydáno 2009
    Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  6. 6
    Proteasome inhibitors in cancer therapy

    Proteasome inhibitors in cancer therapy Autor Elisabet E. Manasanch, Robert Z. Orlowski

    Vydáno 2017
    Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  7. 7
    Evidence That Inhibition of p44/42 Mitogen-activated Protein Kinase Signaling Is a Factor in Proteasome Inhibitor-mediated Apoptosis

    Evidence That Inhibition of p44/42 Mitogen-activated Protein Kinase Signaling Is a Factor in Proteasome Inhibitor-mediated Apoptosis Autor Robert Z. Orlowski, George W. Small, Yue Shi

    Vydáno 2002
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  8. 8
    Pheochromocytoma/Paraganglioma: Review of Perioperative Management of Blood Pressure and Update on Genetic Mutations Associated With Pheochromocytoma

    Pheochromocytoma/Paraganglioma: Review of Perioperative Management of Blood Pressure and Update on Genetic Mutations Associated With Pheochromocytoma Autor Lauren Fishbein, Robert Z. Orlowski, Debbie L. Cohen

    Vydáno 2013
    Získat plný text Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  9. 9
    Biological Effects of the Pim Kinase Inhibitor, SGI-1776, in Multiple Myeloma

    Biological Effects of the Pim Kinase Inhibitor, SGI-1776, in Multiple Myeloma Autor Fabiola Cervantes-Gomez, Lisa S. Chen, Robert Z. Orlowski, Varsha Gandhi

    Vydáno 2013
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  10. 10
    Mitogen-Activated Protein Kinase Phosphatase-1 Is a Mediator of Breast Cancer Chemoresistance

    Mitogen-Activated Protein Kinase Phosphatase-1 Is a Mediator of Breast Cancer Chemoresistance Autor George W. Small, Yue Shi, Linda S. Higgins, Robert Z. Orlowski

    Vydáno 2007
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  11. 11
    Osteoblastic niche supports the growth of quiescent multiple myeloma cells

    Osteoblastic niche supports the growth of quiescent multiple myeloma cells Autor Zheng Chen, Robert Z. Orlowski, Michael Wang, Larry W. Kwak, Nami McCarty

    Vydáno 2014
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  12. 12
    Drug Resistance to Inhibitors of the Human Double Minute-2 E3 Ligase Is Mediated by Point Mutations of p53, but Can Be Overcome with the p53 Targeting Agent RITA

    Drug Resistance to Inhibitors of the Human Double Minute-2 E3 Ligase Is Mediated by Point Mutations of p53, but Can Be Overcome with the p53 Targeting Agent RITA Autor Richard J. Jones, Chad C. Bjorklund, Veerabhadran Baladandayuthapani, Deborah J. Kuhn, Robert Z. Orlowski

    Vydáno 2012
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  13. 13
    Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors

    Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhib... Autor Deborah J. Kuhn, Sally A. Hunsucker, Qing Chen, Peter M. Voorhees, Marian Orłowski, Robert Z. Orlowski

    Vydáno 2008
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  14. 14
    Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors

    Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors Autor Annunziata Gloghini, Daniela Buglio, Noor M. Khaskhely, Georgios Georgakis, Robert Z. Orlowski, Sattva S. Neelapu, Antonino Carbone, Anas Younes

    Vydáno 2009
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  15. 15
    Proteasome inhibitors in multiple myeloma: 10 years later

    Proteasome inhibitors in multiple myeloma: 10 years later Autor Philippe Moreau, Paul G. Richardson, Michèle Cavo, Robert Z. Orlowski, Jesús F. San Miguel, Antonio Palumbo, Jean‐Luc Harousseau

    Vydáno 2012
    Získat plný text Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  16. 16
    Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma

    Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma Autor Michael Wang, Tom Martin, William Bensinger, Melissa Alsina, David S. Siegel, Edward Kavalerchik, Mei Huang, Robert Z. Orlowski, Rubén Niesvizky

    Vydáno 2013
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  17. 17
    <i>In Vitro</i> and <i>In Vivo</i> Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells

    <i>In Vitro</i> and <i>In Vivo</i> Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells Autor Dharminder Chauhan, Ze Tian, Bin Zhou, Deborah J. Kuhn, Robert Z. Orlowski, Noopur Raje, Paul Richardson, Kenneth C. Anderson

    Vydáno 2011
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  18. 18
    Targeted inhibition of interleukin‐6 with CNTO 328 sensitizes pre‐clinical models of multiple myeloma to dexamethasone‐mediated cell death

    Targeted inhibition of interleukin‐6 with CNTO 328 sensitizes pre‐clinical models of multiple myeloma to dexamethasone‐mediated cell death Autor Peter M. Voorhees, Qing Chen, George W. Small, Deborah J. Kuhn, Sally A. Hunsucker, Jeffrey A. Nemeth, Robert Z. Orlowski

    Vydáno 2009
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  19. 19
    MUC20 regulated by extrachromosomal circular DNA attenuates proteasome inhibitor resistance of multiple myeloma by modulating cuproptosis

    MUC20 regulated by extrachromosomal circular DNA attenuates proteasome inhibitor resistance of multiple myeloma by modulating cuproptosis Autor Xiaobin Wang, Yingqing Shi, Hua Shi, Xiaoyu Liu, Liao Ai-jun, Zhuogang Liu, Robert Z. Orlowski, Rui Zhang, Huihan Wang

    Vydáno 2024
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  20. 20
    Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy

    Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide th... Autor Pieter Sonneveld, Roman Hájek, Arnon Nagler, Andrew Spencer, Joan Bladé, Tadeusz Robak, Sen Hong Zhuang, Jean‐Luc Harousseau, Robert Z. Orlowski

    Vydáno 2008
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:

Vyhledávací nástroje: